A Case Study for Determining a Target Expression Cut-Point
View Presentation *Alan Hughes Hartford, AbbVie Keywords: personalized medicine, expression level, oncology Investigating biomarker subgroups in early clinical development may determine who will benefit most from a treatment and provide a greater probability of success for Phase 3. A case study of a targeted therapy in a phase 2 metastatic pancreatic cancer trial will be presented to examine several key elements in the personalized medicine paradigm including the perspective of the investigators enrolling patients, complications of determining a predictive target expression cut point, interpretation of study results, and complications of designing future studies.
|
Key Dates
-
November 1 - December 17, 2013
Online proposal submission for a session, short course and Town Hall Open -
January 6 - March 11, 2014
Online proposal submission for Roundtables Open -
April 30 - May 28, 2014
Abstract Submission Open -
June 4, 2014
Online Registration Opens -
August 8 - August 22, 2014
Invited Abstract Editing -
August 11, 2014
Short Course materials due from Instructors -
September 1, 2014
Housing Deadline -
September 15, 2014
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 22 - September 24, 2014
Marriott Wardman Park, Washington, DC